Article
Treatment Outcomes With Rituximab in 100 Patients With Neuromyelitis Optica: Influence of FCGR3A Polymorphisms on the Therapeutic Response to Rituximab.
JAMA neurology - 1 Sept 2015
Kim Su-Hyun, Jeong In Hye, Hyun Jae-Won, Joung AeRan, Jo Hyo-Jin, Hwang Sang-Hyun, Yun Sooin, Joo Jungnam, Kim Ho Jin
Abstract excerpt
IMPORTANCE: Despite the increased use of rituximab therapy in neuromyelitis optica spectrum disorder (NMOSD), the overall efficacy and safety of long-term rituximab treatment in a large group of patients is uncertain. Furthermore, the identification of a predictor of rituximab response is an important issue for assessing the individual risk-benefit of therapy and making treatment decisions. OBJECTIVE: To assess...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.